Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

26.52 +3.07 (+13.09%)
Official Closing Price Updated: 4:15 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,280,356
Open 25.00
Bid (Size) 26.15 (1)
Ask (Size) 26.50 (1)
Prev. Close 23.45
Today's Range 24.26 - 27.09
52wk Range 18.64 - 27.09
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed significant PFS benefit but OS did not achieve statistical significance.... 
Via Benzinga
Exposures Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
+10.82%
+10.82%
1 Month
+20.05%
+20.05%
3 Month
+19.73%
+19.73%
6 Month
+21.48%
+21.48%
1 Year
+30.96%
+30.96%

More News

Read More
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Via Benzinga
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
Via Benzinga
Topics Stocks
Exposures US Equities
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
From Exelixis, Inc.
Via Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Via The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Via InvestorPlace
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis (EXEL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EXEL Stock Earnings: Exelixis Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.